Michael Burgess
Chief Tech/Sci/R&D Officer en TURNSTONE BIOLOGICS CORP. .
Fortuna: - $ al 31/03/2024
Perfil
Michael M.
Burgess is currently the Director & Chief Medical Officer at Turnstone Biologics Corp.
He is also a Member of The Royal College of Physicians and The Royal College of Paediatrics & Child Health.
Additionally, he serves as a Member-Supervisory Board at iOmx Therapeutics AG.
In his former positions, Dr. Burgess served as an Independent Director at Synlogic, Inc. from 2020 to 2024.
He was also the SVP-Discovery Medicine & Clinical Pharmacology at Bristol Myers Squibb Co. Furthermore, he held positions at Roche Holding AG, Hoffmann-La Roche, Inc., Roche Holding (UK) Ltd., and Roche Ltd., where he held various leadership roles in the field of oncology discovery and translational area.
Dr. Burgess received his graduate degree from the University of Bristol in 1989 and later obtained his doctorate from the same institution in 1999.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 16/10/2023 | 0 ( -.--% ) | - $ | 31/03/2024 | |
SYNLOGIC INC
-.--% | 18/08/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Michael Burgess
| Empresas | Cargo | Inicio |
|---|---|---|
| TURNSTONE BIOLOGICS CORP. | Chief Tech/Sci/R&D Officer | 01/10/2017 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
| The Royal College of Paediatrics & Child Health | Corporate Officer/Principal | - |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Director/Board Member | 20/07/2022 |
Antiguos cargos conocidos de Michael Burgess.
| Empresas | Cargo | Fin |
|---|---|---|
| SYNLOGIC, INC. | Director/Board Member | 20/03/2024 |
| SPRINGWORKS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 16/09/2022 |
Roche Holding (UK) Ltd.
 Roche Holding (UK) Ltd. Pharmaceuticals: MajorHealth Technology Roche Holding (UK) Ltd. manufactures and sells drugs. It operates as a holding company for Roche Products Ltd. and Roche Diagnostics Ltd. Its pharmaceuticals include Copegus, a hepatitis C therapy, HIV inhibitor Fuzeon, and breast cancer therapy, Herceptin. The firm's consumer and professional tests include Accutrend glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics. The company was founded in 1908 and is headquartered in Welwyn Garden City, UK. | Corporate Officer/Principal | 01/01/2010 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formación de Michael Burgess.
| University of Bristol | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ROCHE HOLDING AG | Health Technology |
| SYNLOGIC, INC. | Health Technology |
| SPRINGWORKS THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 5 |
|---|---|
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Roche Holding (UK) Ltd.
Roche Holding (UK) Ltd. Pharmaceuticals: MajorHealth Technology Roche Holding (UK) Ltd. manufactures and sells drugs. It operates as a holding company for Roche Products Ltd. and Roche Diagnostics Ltd. Its pharmaceuticals include Copegus, a hepatitis C therapy, HIV inhibitor Fuzeon, and breast cancer therapy, Herceptin. The firm's consumer and professional tests include Accutrend glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics. The company was founded in 1908 and is headquartered in Welwyn Garden City, UK. | Health Technology |
Roche Ltd.
 Roche Ltd. Financial ConglomeratesFinance Roche Ltd. provides investment services. | Finance |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Health Technology |
| Turnstone Biologics Corp. |
- Bolsa de valores
- Insiders
- Michael Burgess
